Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1403.75
-₹42.20(-2.43%)
At close: 4:00 PM EST
₹1403.75
-₹42.20(-2.43%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,764.00
Previous CloseN/A
Volume578.66K
Average Volume (3M)6.78K
Market Cap
₹430.32B
Enterprise Value₹392.82B
Total Cash (Recent Filing)₹11.98B
Total Debt (Recent Filing)₹8.09B
Price to Earnings (P/E)37.7
Beta0.14
Next Earnings
Aug 06, 2026EPS Estimate
10.6Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)44.98
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.29
Revenue Forecast (FY)₹107.74B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetIPCA's very low leverage and expanding equity provide durable financial flexibility: the company can fund capex, compliance work, or regulatory registrations without heavy new borrowing. This resilience supports long-term operations in regulated markets and cushions cyclical pharma volatility.
Scale With Solid ProfitabilityMaterial scale combined with healthy gross and net margins indicates efficient manufacturing and a profitable product mix across formulations and APIs. Scale helps absorb fixed costs and supports distribution and export capabilities, enabling sustained competitiveness over months.
Positive Free Cash Flow TrendConsistent positive operating cash flow and a rebound in free cash flow strengthen the firm's ability to self-fund capex, regulatory spend and selective reinvestment. Improved FCF trend provides a durable source for debt reduction, dividends or targeted growth initiatives.
Bears Say
Margin CompressionMeaningful margin erosion versus prior years suggests structural pressure from higher input costs, pricing pressure or less-favorable product mix. Persistent compression would reduce reinvestment capacity and lower return on equity, challenging long-term profitability.
Slowing Revenue GrowthTop-line growth deceleration to low single digits limits operating leverage and the company’s ability to expand earnings absent margin recovery. Over 2–6 months this heightens reliance on launches, approvals, or geographic expansion to reaccelerate sustainable revenue gains.
Moderate Cash ConversionFree-cash-flow conversion materially below historical levels indicates working-capital demands or capex absorbing earnings. Even with positive FCF, lower conversion constrains flexibility for M&A, higher dividends or aggressive deleveraging if the trend persists.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1764.00 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹430.32B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹11.8 earnings per share for the quarter, beating the consensus estimate of ₹10.074 by ₹1.726.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Semiannually dividend of ₹6 which represents an annual dividend yield of 0.28%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 10.6.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹11.8 in its last earnings report, beating expectations of ₹10.074. Following the earnings report the stock price went down -3.753%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―